MedPage Today

First PCSK9 Inhibitor Approved for Blanket Prevention of Heart Disease

The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...
Healio

FDA approves monthly PCSK9 inhibitor for high cholesterol

Please provide your email address to receive an email when new articles are posted on . The FDA approved a third-generation PCSK9 inhibitor to reduce cholesterol in certain high-risk patients. The ...
Healio

Oral PCSK9 inhibitor lowers LDL by up to 60%

Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.
Medscape

In Global Trial, PCSK9 Inhibitor Provides Major Protection Against First CV Event

NEW ORLEANS — The first global randomized trial of the PCSK9 inhibitor evolocumab for the prevention of a primary major adverse cardiovascular event (MACE) found a relative reduction in risk similar ...
BioWorld

In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...
MedPage Today

Third-Generation PCSK9 Inhibitor Approved for High Cholesterol

The FDA approved lerodalcibep (Lerochol) injections for the treatment of elevated LDL cholesterol in adults, maker LIB Therapeutics announced. A third-generation PCSK9 inhibitor, lerodalcibep is ...
FierceBiotech

AstraZeneca's oral PCSK9 inhibitor halves cholesterol in phase 2 trial

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the goal of a phase 2 trial in patients with a lipid disorder. The candidate in ...
Monthly Prescribing Reference

Oral PCSK9 Inhibitor Enlicitide Reduces LDL-C in Adults With Hypercholesterolemia

Findings showed the trial met the primary endpoint, with enlicitide demonstrating a statistically significantly meaningful reduction in LDL-C compared with placebo. Topline data were announced from a ...
Morningstar

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment ...
EurekAlert!

Inhibition of PCSK9: a promising enhancer for anti-PD-1/PD-L1 immunotherapy

Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...
PharmiWeb

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

Scribe expects to initiate a first-in-human hypercholesterolemia study in mid-2026 with STX-1150, its lead cardiometabolic assetSTX-1150 is designed to deliver durable therapeutic LDL-C lowering with ...